HKMPY Company Profile and Key Details

Q: Who are the executives of HKMPY?

Mr. Riad MishlawiPres of InjectablesMr. Hussein ArkhaghaCompany Sec. & Chief CounselMr. Mazen Samih Taleb DarwazahExecutive Vice Chairman & Pres of MENAMr. Khalid Waleed Hosny Al NabilsiChief Financial OfficerMr. Brian HoffmannPres of GenericsMs. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGlobal Head of Intellectual Property (IP) & Gen. Counsel for USMs. Majda LabadiExecutive Vice President of Organisational Devel.Engineer Said Samih Taleb DarwazahExecutive Chairman & Chief Executive OfficerMr. Bassam Wael Rushdi Kanaan CFA, CPAExecutive Vice President of Corporation Devel. and M&A

OTC : HKMPY

Hikma Pharmaceuticals

$39.20

Open: 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Hikma Pharmaceuticals PLC (HKMPY) stock remained unchanged at $39.20 a share on OTC. The stock opened at $39.20, fluctuating between $39.20 to $39.20 during the session.

Stock Snapshot

39.2

Prev. Close

4.31B

Market Cap

39.2

Day Low

10.83

P/E Ratio

3.62

EPS (TTM)

2.96

Cash Flow per Share

39.2

Open

110.05M

Number of Shares

39.2

Day High

139.2%

Free Float in %

19.93

Book Value

180

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 06, 2026	38.69	39.20	38.69	39.20	359
Apr 23, 2026	37.50	37.50	37.50	37.50	1.13K
Apr 20, 2026	37.30	37.30	37.30	37.30	222
Apr 17, 2026	37.07	37.07	37.07	37.07	547
Apr 16, 2026	37.72	37.72	36.14	36.14	1.66K
Apr 14, 2026	37.25	37.25	36.38	36.38	1.19K
Apr 06, 2026	35.35	35.35	35.35	35.35	209
Apr 01, 2026	35.06	35.06	35.06	35.06	359
Mar 30, 2026	33.23	33.23	33.23	33.23	343
Mar 25, 2026	34.17	34.17	34.00	34.00	793
Mar 24, 2026	32.40	33.05	32.40	33.05	782
Mar 23, 2026	32.98	32.98	32.98	32.98	281
Mar 20, 2026	34.88	34.88	33.75	34.13	1.01K
Mar 19, 2026	33.56	34.20	33.56	34.20	876
Mar 18, 2026	33.49	33.50	33.49	33.50	370
Mar 17, 2026	34.76	34.76	34.64	34.64	721
Mar 16, 2026	33.00	33.43	32.78	33.43	1.54K
Mar 11, 2026	31.80	31.80	31.00	31.00	757
Mar 09, 2026	31.84	32.14	31.84	32.14	1.46K
Mar 03, 2026	33.20	33.40	33.07	33.11	1.16K

Contact Details

London, W1S 2HR

United Kingdom

https://www.hikma.com 442 073 992760

About Company

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Stock Peers

MKGAF

-6.5-3.38%

MERCK Kommanditgesellschaft auf Aktien$186.00 SGIOF

Shionogi & Co., Ltd.$43.89 ESALF

Eisai Co., Ltd.$43.00 MKKGY

-0.85-2.24%

MERCK Kommanditgesellschaft auf Aktien$37.11 IPSEY

Ipsen S.A.$33.00 TKPHF

Takeda Pharmaceutical Company Limited$26.83 TEVJF

5.26+43.91%

Teva Pharmaceutical Industries Limited$17.24 APNHY

Aspen Pharmacare Holdings Limited$12.52 TAIPY

Taisho Pharmaceutical Holdings Co., Ltd.$12.00 GTBIF

-0.38-3.20%

Green Thumb Industries Inc.$11.49

Company Overview

The stock is currently mid-range between its 52-week high and low $31.80 and $56.94. With a market capitalization of about $4.31 billion, Hikma Pharmaceuticals PLC is classified as a mid-cap and shows lower-than-market volatility (beta ~0.64). Key stats such as the average daily volume over the past year has been around 565.00 shares, volume is running light vs its 52-week average. Headquartered in London, None, Hikma Pharmaceuticals PLC operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Said Samih Taleb Darwazah, the company employs approximately 9,500 people and listed since February 07, 2012. Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

Technical Performance

Average 10-day trading volume of 359.00 shares is below the 3-month average of 1.02 thousand, indicating normal recent market interest.

Valuation Metrics

Hikma Pharmaceuticals PLC trades at a P/E ratio of 10.75, slightly below the S&P 500 average, with a price-to-sales ratio of 1.29 and a price-to-book ratio of 1.66 suggesting the stock is closer to book value. The P/FCF stands at 22.14, also above market averages.

Dividend & Fair Value

Hikma Pharmaceuticals PLC last paid a dividend of 1.68 per share, this equals a trailing yield of roughly inf%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $87.07. This means the shares are trading below this model’s fair value.

Financial & Profitability Overview

Over the trailing twelve months, Hikma Pharmaceuticals generated $2.88B in revenue, or $25.86 per share. Gross margin was 48.35%, operating margin 12.77%, and net profit margin 6.61%. Returns are modest, with ROA at 4.06% and ROE at 8.64%.
On valuation metrics, Hikma Pharmaceuticals trades at a P/E of 10.75, P/S of 1.29 and P/B of 1.66. The current ratio is 1.82 and quick ratio is 1.06. Operationally, the company’s inventory turnover is 1.76 and cash conversion cycle is 191.00 days. Debt-to-equity is 0.64, supported by a cash flow-to-debt ratio of 0.24.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Hikma Pharmaceuticals posted revenue of $2.88B, down slightly from $2.52B in the prior quarter. Gross profit was $1.39B (margin 48.35%). Operating income was $367.00M (margin 12.8%). Net income was$190.00M (EPS $1.72).
The company ended the quarter with $205.00M in cash and short-term investments, a total debt of $1.19B, and net debt of $986.00M. Total assets were $4.68B, with equity of $2.21B. Financials further reflected stability, with operating cash flow of $608.00M, free cash flow of $404.00M, and capital expenditures of - $204.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Hikma Pharmaceuticals PLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Hikma Pharmaceuticals PLC trading at a premium to the broader market with a P/E of 10.75.

Frequently Asked Questions

What is the current Hikma Pharmaceuticals PLC (HKMPY) stock price?

Hikma Pharmaceuticals PLC (OTC: HKMPY) stock price is $39.20 in the last trading session. During the trading session, HKMPY stock reached the peak price of $39.20 while $39.20 was the lowest point it dropped to. The percentage change in HKMPY stock occurred in the recent session was 0% while the dollar amount for the price change in HKMPY stock was $0.00.

HKMPY's industry and sector of operation?

The OTC listed HKMPY is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Hikma Pharmaceuticals PLC designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HKMPY?

Mr. Riad Mishlawi
Pres of Injectables
Mr. Hussein Arkhagha
Company Sec. & Chief Counsel
Mr. Mazen Samih Taleb Darwazah
Executive Vice Chairman & Pres of MENA
Mr. Khalid Waleed Hosny Al Nabilsi
Chief Financial Officer
Mr. Brian Hoffmann
Pres of Generics
Ms. Susan Ringdal
Executive Vice President of Strategic Planning & Global Affairs
Mr. Guy Featherstone
Associate Director of Investor Relations
Mr. Samuel Park
Global Head of Intellectual Property (IP) & Gen. Counsel for US
Ms. Majda Labadi
Executive Vice President of Organisational Devel.
Engineer Said Samih Taleb Darwazah
Executive Chairman & Chief Executive Officer
Mr. Bassam Wael Rushdi Kanaan CFA, CPA
Executive Vice President of Corporation Devel. and M&A

How HKMPY did perform over past 52-week?

HKMPY's closing price is 19.96% higher than its 52-week low of $31.80 where as its distance from 52-week high of $56.94 is -10.54%.

How many employees does HKMPY have?

Number of HKMPY employees currently stands at 9,500.

Link for HKMPY official website?

Official Website of HKMPY is: https://www.hikma.com

How do I contact HKMPY?

HKMPY could be contacted at phone 442 073 992760 and can also be accessed through its website. HKMPY operates from 1 New Burlington Place, London, W1S 2HR, United Kingdom.

How many shares of HKMPY are traded daily?

HKMPY stock volume for the day was 180 shares. The average number of HKMPY shares traded daily for last 3 months was 565.

What is the market cap of HKMPY currently?

The market value of HKMPY currently stands at $4.31B with its latest stock price at $39.20 and 110.05M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	9500
Beta	0.65
Sales or Revenue	$2.88B
5Y Sales Change%	0.497%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

HKMPY Company Profile and Key Details

Hikma Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics